rly-4008
relay therapeutics
['rly-4008']
rly-4008 a highly selective fgfr-2 inhibitor reached orr 82.4% in fgfr-2 fusions or rearrangement patients with #cholangiocarcinoma naive to fgfr2 inhibitors #esmo2022 #esmo22 pending data on os and pfs .. 
Medical Oncologist, GI tumors and NET, @INCMNSZ